This is the question that lands in our inbox most: I’m losing weight on retatrutide, should I add tesamorelin to hold on to my muscle?
It is a fair worry, and the thinking behind it is neat. Nobody wants to drop the kilos and wake up weaker. Here is what we know, what we don’t, and the one catch you should understand first.
At a glance
- The logic is sound. Retatrutide takes weight off fast, and some of it is lean tissue. Tesamorelin raises growth hormone, which is anabolic.
- The proof is missing. We know of no published trial of the two together, so “it protects muscle” is a theory today.
- Blood sugar is the catch. Tesamorelin can raise it. Retatrutide is built to lower it.
- Sleep is promising, not proven. The hormone tesamorelin copies has deepened sleep in small studies. Tesamorelin itself has no completed sleep trial.
- Lifting and protein are still the best-supported way to keep muscle.
- The habits you build while losing weight decide what happens when you stop.
Why people pair them
When weight drops fast, not all of it is fat. In a DEXA body-scan substudy of 189 people with type 2 diabetes on retatrutide, roughly six to seven parts in ten of the weight lost was fat, and the rest was lean tissue. Reports of the exact split differ, so treat it as a rough guide. Lean tissue is not only muscle, but muscle is part of it.
Muscle is not about looks. It carries your strength, your balance, your metabolism and how well your body handles blood sugar as you age. Lose too much of it and you undo part of the point. We made the longer case in strength training is the closest thing to an anti-ageing intervention.
Enter growth hormone, which is anabolic and mobilises fat. Tesamorelin prompts your body to make more of its own. On paper, retatrutide drives the fat loss and tesamorelin helps you hold on to what you want to keep.
Retatrutide and tesamorelin side by side
| Retatrutide | Tesamorelin | |
|---|---|---|
| What it is | Triple agonist: acts on the GLP-1, GIP and glucagon receptors | Synthetic GHRH: prompts your body to release more of its own growth hormone |
| Main effect studied | Large overall weight loss | Less visceral (deep belly) fat |
| How often, in trials | Once a week | Once a day |
| Blood sugar | Lowers it | Can raise it |
| Status | Investigational, not approved anywhere | Approved in the US since 2010 for HIV-related abdominal fat |
Retatrutide is an investigational once-weekly injection from Eli Lilly. In its 2023 phase two trial (338 adults), the highest dose averaged a 24.2% weight loss at 48 weeks. In May 2026 Lilly reported 28.3% at 80 weeks in the first phase three trial, TRIUMPH-1 (company-reported). Lilly has said it plans to file with the FDA in the first quarter of 2027. New to the receptor side? Retatrutide vs tirzepatide vs semaglutide explains what each one adds.
Tesamorelin’s approval is narrow. It tells you what it has been shown to do, and in whom: reduce excess abdominal fat in adults living with HIV. It does not tell you what it does next to a triple agonist in someone without HIV.
What the evidence says
We know of no published trial that tests the two together. So any claim that the combination preserves muscle is theoretical today. That does not make it wrong. It means the research is early. Even on its own, tesamorelin’s muscle case is thin: its trials were about abdominal fat, and none was built to test muscle protection during rapid weight loss.
What about sleep?
You will hear that tesamorelin improves sleep. Here is the honest picture. Growth hormone releasing hormone, the hormone tesamorelin copies, has been shown to increase deep (slow-wave) sleep in small studies of healthy volunteers when given in pulses. We found no completed trial that measured tesamorelin’s effect on sleep. A tesamorelin sleep trial in people with insomnia was registered, but we found no published results, and a study of GHRH in older adults reported no improvement in self-rated sleep. Some people do report sleeping better. That is worth noting, and it is not the same as proof.
Two ways people run it
The first uses tesamorelin during the loss phase to try to protect lean tissue. The second finishes the weight loss on retatrutide and then moves to tesamorelin alongside training to help rebuild. Both have an appealing logic. Both are untested, and both share the same ground rules: involve a doctor, keep an eye on blood sugar, and do not treat a theory as a plan.
Use the quiet appetite to build habits
A weight-loss peptide is a window, not a plan. While appetite is quiet, you have a rare stretch where the right choices are easy. What you build in it decides what happens when it closes.
The evidence says the same. In the STEP 1 follow-up, people who stopped semaglutide regained about two-thirds of what they had lost within a year (a subset of 327 people, exploratory data). The trial also paired the drug with lifestyle counselling. The authors concluded that obesity is chronic and needs ongoing management. We would add that habits are the part you can build while the drug is doing the heavy lifting.
- Anchor every meal on protein. It is the habit that keeps muscle now and keeps you full later.
- Get a lifting routine in place while energy and motivation are there, and make it something you would keep doing without the compound.
- Protect your sleep. It makes every other habit easier.
- Track more than the scale: waist, strength in the gym, how your clothes fit and how you feel.
Worth sitting with. If the compound disappeared tomorrow, which of your new habits would still be there? Whatever the answer is, that is what you are really building. Decide now what your plan is for the year after.
The risks worth knowing
- Blood sugar. Tesamorelin’s prescribing information warns it can cause glucose intolerance. That pulls straight against retatrutide.
- Tesamorelin side effects listed as most common include joint pain, injection site redness and itching, limb pain, swelling (fluid retention) and muscle pain.
- Retatrutide side effects in trials were mostly gut-related (nausea, vomiting, diarrhoea), plus a dose-dependent rise in heart rate.
- Sport. Growth hormone releasing compounds, tesamorelin included, are on the World Anti-Doping Agency prohibited list. Tested athletes should stay away, and check the current list.
- Product quality. Unregulated sources can mean mislabelled, underdosed or contaminated product. Wherever you buy, ask for the batch documentation first. We send what our suppliers provide, on request.
What reliably protects muscle

- Lifting two to four times a week.
- Enough protein, spread across the day. Protein, amino acids and peptides shows where those overlap and where they don’t.
- A rate of loss that is not extreme.
- A DEXA scan before you start, so you know what you are actually losing and not just what the scale says.
None of it is new or exciting, which is exactly why it gets skipped. If you only do one thing from this page, do this.
Where we stand
It is a popular pairing, we supply both, and we would rather you buy knowing the limits than the other way round. Every retatrutide option is compared on price per milligram on our retatrutide page. Tesamorelin is in stock as a 2mg self-mix vial from UPA Labs or Nova Labs, and as one of the three compounds in our Shredded pen, alongside AOD-9604 and MOTS-c. We will update this page when a trial lands.
Frequently asked questions
Does tesamorelin improve sleep?
It might, but it has not been shown. Growth hormone releasing hormone has increased deep sleep in small studies of healthy volunteers, but we found no completed trial of tesamorelin itself on sleep.
Should I use tesamorelin after reaching my goal on retatrutide?
Some people do, hoping to help rebuild muscle alongside training. It has not been studied, so there is no trial evidence either way. Speak to a doctor, and watch your blood sugar.
Does retatrutide cause muscle loss?
Some of the weight lost on retatrutide is lean tissue, though most is fat. Lifting and enough protein are the best-supported ways to limit the lean mass you lose.
Is retatrutide approved in South Africa?
No. It is not registered with SAHPRA and has not been approved by any regulator. Lilly has said it plans to file for FDA approval in the first quarter of 2027.
Is tesamorelin banned in sport?
Yes. Tesamorelin is named as a growth hormone releasing hormone analogue on the World Anti-Doping Agency prohibited list. Check the current list before competing.
Sources
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 2023.
- Eli Lilly TRIUMPH-1 topline results, 21 May 2026 (company-reported): coverage in AJMC. Filing plan: Pharmacy Times, July 2026.
- Retatrutide body composition (DEXA) substudy in type 2 diabetes. Lancet Diabetes & Endocrinology, 2025.
- EGRIFTA (tesamorelin) US prescribing information: indication, glucose intolerance warning and common adverse reactions.
- World Anti-Doping Agency. The Prohibited List, section S2 (GHRH and its analogues).
- Sleep: greater efficacy of episodic than continuous GHRH in promoting slow-wave sleep (1996); JAMA Neurology letter on GHRH in older adults; registered tesamorelin sleep trial NCT02931474.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022.
This article is for educational purposes only and is not medical advice. Neither retatrutide nor tesamorelin is registered for use in South Africa as far as we can establish. Our piece on whether peptides are legal in South Africa covers what that means.
Everything we sell is supplied for research use only and is not a registered medicine. Nothing here is medical advice.
Browsing by goal? See peptides for muscle growth.
Keep reading: retatrutide vs tirzepatide vs semaglutide, how to get more from retatrutide for food, training and supplements, or how to read a peptide study.

